Sclerosis  >>  ozanezumab (GSK 1223249)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ozanezumab (GSK 1223249) / GSK
NCT01424423: NOGO-A in Multiple Sclerosis FTIH

Terminated
1
3
RoW
Placebo, GSK1223249
GlaxoSmithKline
Multiple Sclerosis
08/10
08/10
NCT00875446: First Time in Human Study of GSK1223249 in Amyotrophic Lateral Sclerosis

Completed
1
76
US, Europe
PLACEBO, GSK1223249
GlaxoSmithKline
Amyotrophic Lateral Sclerosis
09/11
09/11

Download Options